Redx has suspended trading of its shares after a creditor stepped up its attempt to recoup a loan.

The U.K. has been closing the gap on life sciences sectors in Boston and San Francisco, but uncertainty caused by Brexit may undermine those efforts, said the…

G1 Therapeutics thinks it has a winner on its hands with CDK4/6 inhibitor trilaciclib and is embarking on an initial public offering to give it the resources…

AstraZeneca's European pharma VP is reported to be on "gardening leave" after his employer sues for breaching his employment contract.

Frequency Therapeutics has just raised $32 million in a financing round it hopes will help it bring its therapy for noise-induced hearing loss into the clinic.

Axovant Sciences is capitalizing on the attention it has received from welcoming biotech icon David Hung as its new CEO with a $125 million share offering.

Israel's Bioblast Pharma has abandoned plans for a securities offering, blaming what it called "adverse market conditions" for the decision.

With two failed trials, Aviragen is looking at strategic alternatives to breathe new life into its business, and says it will cut its headcount by 25%.